Literature DB >> 27068220

Unforeseeable presentation of Chryseobacterium indologenes infection in a paediatric patient.

Geethalakshmi Srinivasan1, Swapna Muthusamy1, Vinod Raveendran1, Noyal Mariya Joseph2, Joshy Maducolil Easow3.   

Abstract

BACKGROUND: We report for the first time a case of community acquired Chryseobacterium indologenes soft tissue infection in an immunocompetent patient. CASE
PRESENTATION: A 11 year female child, from South-Asia of Indian origin presented with fever, pain and swelling in right leg for 3 days with no significant past history. Incision and drainage was done and pus was sent for culture and sensitivity. Radiological investigation showed subtle irregular soft tissue density. Pus culture grew multidrug resistant C. indologenes.
CONCLUSION: Though of low pathogenicity, our case emphasises its unpredictable nature and the need to determine minimum inhibitory concentration breakpoints for therapy.

Entities:  

Keywords:  Case report; Cellulitis; Chryseobacterium indologenes; Soft-tissue infection

Mesh:

Year:  2016        PMID: 27068220      PMCID: PMC4828799          DOI: 10.1186/s13104-016-2022-6

Source DB:  PubMed          Journal:  BMC Res Notes        ISSN: 1756-0500


Background

Previously known as Flavobacterium, the genus Chryseobacterium comprising six species are non-glucose fermenting bacilli. Chryseobacterium indologenes species was first isolated in 1993 from tracheal aspirate of a patient complicated with ventilator associated pneumonia. The clinical significance of the infections due to C. indologenes is poorly studied as not many cases are reported in literature and is also a rare human pathogen. Commonly seen in the environment, these are known to cause a spectrum of infections usually in hospitalized and immunocompromised patients, and in infants. Here we describe a case of C. indologenes infection in an immunocompetent child.

Case presentation

A 11 year old female child from South-Asia of Indian origin, presented to the orthopaedics department with complaints of fever, non-traumatic pain and swelling in the right leg for about 3 days. There was no significant past history. She was septic and was noted to have a diffuse swelling over the upper third of right leg with skin erythema, warmth and tenderness. No discharging sinuses were noted. Blood investigations showed a raised white cell count and marginally increased erythrocyte sedimentation rate (ESR). Rest of the haematological and biochemical markers were within normal limits. Blood sample was sent for culture and sensitivity which showed no growth. Anteroposterior and lateral views of plain radiograph of the right leg showed normal tibia and fibula with subtle irregular altered soft tissue density in the lateral aspect of the mid third of the leg (Fig. 1). Incision and drainage was performed the following day under general anaesthesia. Thick purulent discharge was drained and about 5 ml of the discharge was sent for culture and sensitivity. The wound was left open and dressed appropriately (Table 1).
Fig. 1

Plain radiograph anteroposterior projection demonstrating patchy irregular increased soft tissue densities in the lateral aspect of the middle third of the right leg as marked by the arrow

Table 1

Timeline of case management

TimeProcess followedObservation and management
Day 1HistoryFever, pain and swelling for 3 days
Physical examinationSwelling with erythema, warmth and tenderness
Blood count, erythrocyte sedimentation rateRaised white cell countMarginally elevated erythrocyte sedimentation rate
X-rayNormal tibia and fibula with subtle irregular altered soft tissue density in the lateral aspect of the mid-third of the leg
Blood cultureNo growth after 7 days of incubation
TreatmentPatient was empirically given parenteral cefotaxime, metronidazole and gentamicin
Day 2Incision and drainage under general anaesthesiaThick purulent discharge was obtained and sent for culture and sensitivity
Gram stainPlenty of pus cells and gram negative bacilli were seen
CultureOn incubation
Day 3Genus identification by conventional method Chryseobacterium spp.Subjected for VITEK-2 identification and antibiotic sensitivity testing
Day 4Species identification by conventional and VITEK-2 C. indologenes Minimum inhibitory concentration values by VITEK-2 as in Table 2
Day 5Switching of antibioticsCefotaxime was changed over to ceftazidimeGentamicin was discontinued
Day 5–12Local examinationWound was healing well, secondary closure done and patient was discharged
Plain radiograph anteroposterior projection demonstrating patchy irregular increased soft tissue densities in the lateral aspect of the middle third of the right leg as marked by the arrow Timeline of case management Gram staining of the purulent material showed numerous pus cells and gram negative bacilli. Inoculation in blood agar showed dark yellow pigmented colonies with no hemolysis (Fig. 2). On nutrient agar yellow pigmented colonies were seen and were noticed to turn to red when 10 % potassium hydroxide (KOH) was added on to the culture (Fig. 3). It did not grow in Mac Conkey agar. The isolate was non-motile, catalase and oxidase positive, indole positive, methyl red negative and Voges–Proskauer’s negative. Urea was not hydrolysed and citrate was not utilized. On triple sugar iron agar, glucose was utilised with gas production. The organism was identified by both conventional method and VITEK-2 systems version: 07.01 as C. indologenes.
Fig. 2

Blood agar showing non-haemolytic yellow pigmented colonies of C. indologenes

Fig. 3

Yellow pigmented colonies of C. indologenes turning to red upon addition of 10 % potassium hydroxide

Blood agar showing non-haemolytic yellow pigmented colonies of C. indologenes Yellow pigmented colonies of C. indologenes turning to red upon addition of 10 % potassium hydroxide Genus was presumptively identified as Chryseobacterium after 24 h and genus confirmation, species identification and sensitivity results were available in 48 h. The minimum inhibitory concentration (MIC) values by VITEK-2 system are in Table 2.
Table 2

Minimum inhibitory concentration values by VITEK-2 system

AntibioticMinimum inhibitory concentration value (µg/ml)Interpretation
Gentamicin≥16Resistant
Amikacin≥64Resistant
Ceftazidime4Susceptible
Piperacillin–tazobactam64Intermediate
Cefaperazone–sulbactam32Intermediate
Imipenem1Susceptible
Meropenem≥16Resistant
Doripenem≥8Resistant
Minocycline≤1Susceptible
Levofloxacin0.25Susceptible
Ciprofloxacin≤0.25Susceptible
Cotrimoxazole≤20Susceptible
Aztreonam≥64Resistant
Minimum inhibitory concentration values by VITEK-2 system Our isolate was susceptible to imipenem and resistant to meropenem and doripenem. Chryseobacterium species are intrinsically resistant to most beta lactams including carbapenems due to the production of chromosomally mediated metallobetalactamases (MBL). The isolate was a MBL producer which was confirmed by double disk diffusion method with ethylene diamine tetraacetic acid (EDTA). Patient was empirically started on parenteral cefotaxime, metronidazole and gentamicin, was changed over to intravenous ceftazidime 1 g twice daily and metronidazole infusion 500 mg thrice daily for 5 days based on the sensitivity report following which significant clinical improvement was noted. Subsequently secondary closure was done 10 days later. The wound healed well and the patient was discharged on oral antibiotics with follow up. Consent for publication was obtained from the patient’s parent.

Discussion

Infection due to C. indologenes in humans is a rare occurrence and is usually nosocomial. These are mainly found in soil, plants, water and foodstuffs. They are not found in human flora. Within the hospital premises, they exist in water systems and wet surfaces and can survive in chlorinated water [1]. Chryseobacterium species are gram-negative, aerobic, non-motile, oxidase positive, catalase positive, indole positive, producing a distinct yellow orange pigment due to production of flexirubin. Indole was produced in tryptophan broth. The genus Chryseobacterium belongs to the family Flavobacteriaceae. The commonly isolated species includes C. meningosepticum, C. multivorum, C. odoratum, C. breve and group IIb Chryseobacterium species which includes C. indologenes and C. gleum. Of these C. meningosepticum is the most pathogenic causing neonatal meningitis [2]. Chryseobacterium infections are frequently associated with the presence of indwelling devices like intra-vascular catheters etc., in immunocompromised patients or in patients on long-term broad-spectrum antibiotics. Factors influencing the development of Chryseobacterium infection include a suitable entry port, invasive procedures, neutropenia, production of biofilm on foreign materials, prolonged use of antibiotics and immunodeficiency [3, 4]. Infections associated with Chryseobacterium species include bacteremia, wound sepsis, indwelling device associated infections, ocular infections and intra-abdominal infections. In our patient it was associated with cellulitis, soft tissue infection and abscess formation. They are usually isolated from clinical specimens but rarely from blood as were in our case [4]. Most of the C. indologenes infections described in literature were hospital acquired and were seen in patients with underlying debilitating diseases [4-9]. Mostly our isolate is community acquired, as the sample grew Chryseobacterium from pus collected intraoperatively on the second day of admission. During the above said period, environmental surveillance samples did not grow Chryseobacterium. Interestingly our patient was not immunosuppressed or was on any long term antibiotics or with indwelling devices, making this case unusual in presentation. Douvoyiannis et al. [10] had reported the first case of C. indologenes in a 33 day old infant in 2010. Hendaus et al. [11] reported the second case of C. indologenes infection from healthy newborn in 2013. Ours would be the third case of C. indologenes infection reported from an immunocompetent paediatric patient. Not much data is available in literature on the choice of appropriate antibiotic for empirical treatment in C. indologenes infections [12]. This uncertainty is attributed to the wide spectrum of antimicrobial resistance, lack of gold standard susceptibility testing, unpredictable nature and non-establishment of MIC breakpoints for these organisms [13]. Further, biofilm and proteases production by C. indologenes species reduces its antimicrobial susceptibility [14]. Based on the results of SENTRY antimicrobial surveillance program during 1997–2001, the highest prevalence of Chryseobacterium was seen among the elderly. The most appropriate antibiotics that can be used for treating Chryseobacterium infections are newer fluoroquinolones (MIC 90–1 µg/ml) followed by rifampin (MIC 90–2 µg/ml). C. indologenes isolates showed adequate susceptibilities to trimethoprim-sulfamethoxazole, ciprofloxacin and piperacillin–tazobactam [15]. Variable susceptibility to vancomycin has been reported in literature [16]. Chryseobacterium indologenes is invariably resistant to aminoglycosides, shows varying degree of resistance to carbapenems, cephalosporins, piperacillin–tazobactam and are susceptible to fluroquinolones and cotrimoxazole. Based on the sensitivity pattern reported in SENTRY [15] and other literatures [9, 10, 17], there was no evident difference for community acquired isolates as compared with hospital acquired strains. In this study, the isolate was resistant to meropenem and susceptible to imipenem by VITEK-2 systems. This could be due to different mechanisms involved in imipenem and meropenem resistance. Meropenem resistance is due to efflux systems and imipenem resistance is by porin mutations. Over expression of MexAB-OprM, an efflux system pumps out meropenem but not imipenem [18]. As the isolate was confirmed to be a MBL producer by imipenem-EDTA double disc diffusion test, all the carbapenems were reported as resistant for therapeutic purpose. Disk diffusion methods are not reliable and thus susceptibility testing by broth micro dilution method should be performed [19].

Conclusion

Listed as one of the nosocominal infections, C. indologenes infections known for its rare and sporadic incidence can cause potentially serious infections in humans. As described they can cause significant infections in immunocompetent individuals as well. More extensive and long term studies are required to understand the demographics, pathogenicity, virulence factors, arbitrary antimicrobial resistance and appropriate antimicrobial therapy.
  17 in total

1.  Cellulitis and bacteraemia due to Chryseobacterium indologenes.

Authors:  B T Green; P E Nolan
Journal:  J Infect       Date:  2001-04       Impact factor: 6.072

2.  Increasing incidence of nosocomial Chryseobacterium indologenes infections in Taiwan.

Authors:  P R Hsueh; L J Teng; P C Yang; S W Ho; W C Hsieh; K T Luh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-08       Impact factor: 3.267

3.  Catheter-related bacteremia due to Chryseobacterium indologenes in a bone marrow transplant recipient.

Authors:  M Akay; E Gunduz; Z Gulbas
Journal:  Bone Marrow Transplant       Date:  2006-02       Impact factor: 5.483

4.  Chryseobacterium indologenes non-catheter-related bacteremia in a patient with a solid tumor.

Authors:  George B Christakis; Stavroula P Perlorentzou; Irene Chalkiopoulou; Athanasios Athanasiou; Nikolas J Legakis
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

5.  Flavobacterium indologenes bacteremia: clinical and microbiological characteristics.

Authors:  P R Hsueh; T R Hsiue; J J Wu; L J Teng; S W Ho; W C Hsieh; K T Luh
Journal:  Clin Infect Dis       Date:  1996-09       Impact factor: 9.079

6.  Chryseobacterium indologenes bacteraemia in a diabetic child.

Authors:  Antonio Cascio; Giovanna Stassi; Gaetano B Costa; Giuseppe Crisafulli; Immacolata Rulli; Caterina Ruggeri; Chiara Iaria
Journal:  J Med Microbiol       Date:  2005-07       Impact factor: 2.472

7.  Reappraisal of the antimicrobial susceptibilities of Chryseobacterium and Flavobacterium species and methods for reliable susceptibility testing.

Authors:  S L Fraser; J H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

8.  Urinary tract infection by Chryseobacterium indologenes.

Authors:  G Bhuyar; S Jain; H Shah; V K Mehta
Journal:  Indian J Med Microbiol       Date:  2012 Jul-Sep       Impact factor: 0.985

9.  Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp: report from the SENTRY Antimicrobial Surveillance Program (1997-2001).

Authors:  Jeffrey T Kirby; Helio S Sader; Timothy R Walsh; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

10.  Chryseobacterium indologenes Septicemia in an Infant.

Authors:  Turkan Aydin Teke; Fatma Nur Oz; Ozge Metin; Gulsum Iclal Bayhan; Zeynep Gökce Gayretli Aydin; Melek Oguz; Gonul Tanir
Journal:  Case Rep Infect Dis       Date:  2014-07-10
View more
  4 in total

1.  Chryseobacterium Indologenes Pneumonitis in an Infant: A Case Report.

Authors:  Parijat Das; Santosh Karade; Kanwaljit Kaur; Ravi Ramamurthy; Praveer Ranjan
Journal:  J Clin Diagn Res       Date:  2017-06-01

2.  Ventilator-associated pneumonia caused by Chryseobacterium indologenes: a rare infant case and review of the literature.

Authors:  Serkan Atıcı; Zeynep Alp Ünkar; Kübra Erdem; Eda Kepenekli Kadayifci; Ayşe Karaaslan; Aslı Çınar Memişoğlu; Ahmet Soysal; Nurver Ülger Toprak; Güner Söyletir; Eren Özek; Mustafa Bakır
Journal:  Springerplus       Date:  2016-10-07

3.  Challenges in the identification of Chryseobacterium indologenes and Elizabethkingia meningoseptica in cases of nosocomial infections and patients with cystic fibrosis.

Authors:  É B de Carvalho Filho; F A L Marson; C E Levy
Journal:  New Microbes New Infect       Date:  2017-09-13

4.  Bacteremia by Chryseobacterium indologenes in a Patient with Lung Cancer: A Clinical and Microbiological Investigation.

Authors:  Gitali Bhagawati; Ashutosh Bhardwaj; Rekha Sajikumar; Sukhwinder Pal Singh; Sanjeev Prajapati
Journal:  Indian J Crit Care Med       Date:  2019-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.